Want to see ASND full AI Analyst Report?
ASND Stock Chart & Stats
$250.25
-$0.44(-0.17%)
At close: 4:00 PM EDT
$250.25
-$0.44(-0.17%)
Day’s Range― - ―
52-Week Range$188.07 - $282.15
Previous Close$253.42
Volume365.41K
Average Volume (3M)839.06K
Market Cap
$14.62B
Enterprise Value$17.81B
Total Cash (Recent Filing)$811.92M
Total Debt (Recent Filing)$449.89M
Price to Earnings (P/E)17.2
Beta0.51
Next Earnings
Nov 11, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.10
Shares Outstanding62,376,846
10 Day Avg. Volume777,573
30 Day Avg. Volume839,059
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue16.89
Enterprise Value/Gross Profit18.73
Enterprise Value/Ebitda227.94
Forecast
1Y Price Target
$315.41Price Target Upside26.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)14.56
Revenue Forecast (FY)$1.36B
Bulls Say, Bears Say
Bulls Say
Rapid Product Revenue GrowthRapid growth across YORVIPATH, SKYTROFA and newly launched YUVIWEL shows that Ascendis is building a multi-product commercial base. Continued patient enrollment and management’s reiterated growth outlook could support durable revenue expansion as launches mature across additional markets.
Strong Cash Generation And Low LeveragePositive operating and free cash flow, combined with substantial cash and no bank or convertible debt, gives Ascendis financial flexibility to fund launches, clinical development and potential expansion internally. This reduces near-term financing dependence while supporting continued investment in its pipeline.
Broadening Endocrine PipelineThe TransCon platform supports multiple endocrine and rare-disease programs beyond the current commercial products. Positive achondroplasia data and planned annual regulatory filings create opportunities for label expansion and new launches, strengthening the company’s longer-term growth platform.
Bears Say
Profitability Remains Historically InconsistentThe recent profit inflection has not yet been demonstrated across a full business cycle. Prior losses and deeply negative operating margins indicate that earnings and cash generation may remain sensitive to launch timing, investment levels and product performance as Ascendis scales.
Reported Profit Benefited From One-time IncomeThe priority review voucher sale materially increased reported operating and net profit, creating a gap between statutory and adjusted results. Because this income is non-recurring, underlying profitability is better represented by adjusted earnings and may be lower than headline results suggest.
Confirmatory Trial And Regulatory RiskDependence on confirmatory evidence means some product approvals and labels are not entirely insulated from future clinical outcomes. An unfavorable result could affect commercial durability, development priorities and the value of related investments, even as current launches perform well.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $188.07 and its highest was $282.15 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $14.62B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Nov 11, 2026 which is in 21 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Aug 13, 2026. The company reported $3.177 earnings per share for the quarter, beating the consensus estimate of $1.681 by $1.496.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is 0.9.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 62,376,846 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of $3.177 in its last earnings report, beating expectations of $1.681. Following the earnings report the stock price went down -3.613%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$315.41 (26.04% Upside)
$315.41 (26.04% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 433.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $380.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.19%
12-Months-Change
Fundamentals
Return on Equity
190.44%
Trailing 12-Months
Asset Growth
104.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
ASND Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear early successes: double-digit top-line expansion with EUR 315 million in product revenue, blockbuster-level performance from YORVIPATH (EUR 252 million), a successful SKYTROFA base (>20,000 patients), and a promising early U.S. launch for YUVIWEL with rapid enrollments and reimbursement approvals. Robust clinical readouts (COACH arm-span gains) and progressing partnerships reinforce long-term upside. Offsetting these positives were elevated R&D and SG&A spending, reliance on a one-time PRV sale to bolster reported profit (non-IFRS net profit materially lower at EUR 61 million), and legal/regulatory uncertainties (U.S. IP dispute and confirmatory trial dependence). Overall, highlights outweigh the lowlights given accelerating commercial traction, a strong cash position and no debt, but investors should monitor expense trajectory and the legal/regulatory developments.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$315.41
▲(26.04% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ultragenyx Pharmaceutical
―
Xeris Pharmaceuticals
―
―
MBX Biosciences, Inc.
―
Ownership Overview
0.02% Insiders
11.85% Mutual Funds
0.50% Other Institutional Investors
81.80% Public Companies and
Individual Investors